#Ireland #Dublin #Clinical Data #Plantar Fibromatosis #Keenova

Keenova's Groundbreaking Presentation on Plantar Fibromatosis Research

In a noteworthy revelation at the American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting held from February 24th to 27th, 2026, Keenova Therapeutics plc showcased significant clinical data concerning plantar fibromatosis. This progressive condition, characterized by the formation of painful nodules in the foot, currently lacks FDA-approved nonsurgical treatment options, making Keenova’s research a pivotal development in this area.

The clinical data presented focused on the safety and efficacy of collagenase clostridium histolyticum (CCH). Although CCH has yet to receive FDA approval specifically for plantar fibromatosis treatment, Keenova's ongoing Phase 3 clinical trial aims to evaluate its effectiveness and is expected to yield results by mid-2026.

The Importance of the Findings

According to preliminary findings from Study 306, an open-label extension of Keenova's Phase 2 trial, patients undergoing treatment with CCH displayed a safety profile consistent with previous studies. These findings support the potential for CCH to provide long-term safety and efficacy for patients suffering from plantar fibromatosis.

Dr. Marek Honczarenko, Keenova's Executive Vice President and Chief Scientific Officer, expressed optimism about the data’s implications, stating, "We are pleased to share with the medical community these important data that help advance our understanding of this burdensome condition. Our commitment is to advance a nonsurgical treatment option for patients with plantar fibromatosis."

Study Insights

The Phase 2 trial’s results built on earlier findings that indicated improvements in nodule hardness and pain reduction. Participants in this study experienced a 180-day observation period without treatment before entering an optional treatment phase for new or previously treated nodules. Those opting out of re-treatment continued under long-term observation. The primary endpoint was focused on safety, complemented by additional efficacy evaluations through patient and investigator reports.

Understanding Plantar Fibromatosis

Plantar fibromatosis, also known as Ledderhose disease, is a hyperproliferative fibrous tissue disorder that can result in the formation of painful collagen nodules along the plantar fascia. While there is currently no cure available for plantar fibromatosis, management options often range from custom insoles to topical treatments, anti-inflammatory medications, radiation, and, in severe cases, surgical intervention to remove nodules.

Keenova Therapeutics, headquartered in Dublin, Ireland, is a prominent developer of therapeutic solutions targeting rare or unmet medical needs. Their portfolio spans a variety of therapeutic areas, reinforcing their dedication to helping patients lead healthier lives. With facilities across the U.S. in states such as Louisiana and New Jersey, Keenova emphasizes its commitment to innovative therapeutic advancements.

Looking Forward

As Keenova progresses towards its pivotal Phase 3 study, stakeholders in the medical community are keenly awaiting the comprehensive results expected in 2026. This research not only holds the potential to expedite treatment solutions for plantar fibromatosis patients but also reinforces the broader commitment to developing therapies for underaddressed medical conditions.